NeuroSense Expands Global IP Protection Strategy With Granted Australian Patent Covering PrimeC Composition

Rhea-AI Summary

NeuroSense (Nasdaq: NRSN) announced that IP Australia granted Australian Patent No. 2022370513 for compositions comprising ciprofloxacin and celecoxib, extending patent protection for PrimeC through October 2042.

The grant follows a corresponding U.S. patent (12,097,185) and strengthens the company’s global exclusivity strategy as PrimeC advances toward pivotal Phase 3 development in ALS after positive Phase 2b PARADIGM results and FDA clearance of the Phase 3 protocol.

Positive

• Australian patent No. 2022370513 granted for PrimeC composition
• Patent protection for PrimeC extended through October 2042
• Corresponding U.S. patent (12,097,185) already granted, reinforcing exclusivity
• Supports potential commercialization and long-term IP strategy in key markets
• PrimeC described as Phase 3-ready in ALS after positive Phase 2b PARADIGM results

Negative

• None.

Key Figures

Patent term: Through October 2042

1 metrics

Patent term Through October 2042 Australian PrimeC composition patent coverage

Market Reality Check

Price: $0.9399 Vol: Volume 151,449 vs 20-day ...

low vol

$0.9399 Last Close

Volume Volume 151,449 vs 20-day average 256,994 (relative volume 0.59) shows no surge in trading activity. low

Technical Shares at 0.9399 are trading below the 200-day MA of 1.3, despite a 8.03% daily gain.

Peers on Argus

NRSN gained 8.03% while peers showed mixed, smaller moves (e.g., TENX +2.74%, DA...

2 Up

NRSN gained 8.03% while peers showed mixed, smaller moves (e.g., TENX +2.74%, DARE -2.31%, ITRM +2.20%). Momentum scanner shows ITRM and RVPH up ~5%, but NRSN’s larger move suggests stock-specific reaction to its patent news.

Historical Context

5 past events · Latest: Jan 21 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Jan 21	Alzheimer’s IP expansion	Positive	-5.2%	New U.S. patent for PrimeC in Alzheimer’s extending protection to 2043.
Jan 08	SAB appointment	Positive	+12.4%	Renowned Alzheimer’s expert joined SAB to support PrimeC programs.
Dec 22	Alzheimer’s safety data	Positive	+3.8%	Phase 2 Alzheimer’s study reported favorable safety and tolerability for PrimeC.
Dec 04	Canada regulatory plans	Positive	-3.5%	Resumed Canadian ALS regulatory activity, planning pre‑NDS meeting and potential NDS.
Nov 24	FDA Phase 3 clearance	Positive	-3.6%	FDA authorized pivotal Phase 3 PARAGON trial of PrimeC in ALS.

Pattern Detected

Recent positive regulatory and clinical updates have produced mixed reactions, with several instances where favorable news coincided with negative price moves.

Recent Company History

Over the last few months, NeuroSense has reported several milestones around PrimeC. These include FDA clearance for a pivotal Phase 3 ALS trial on Nov 24, 2025, Health Canada regulatory planning toward a potential NDS submission by mid‑2026, and favorable Phase 2 Alzheimer’s safety data. More recently, the company received a U.S. patent for Alzheimer’s use extending to 2043 and added a prominent Alzheimer’s expert to its SAB. Today’s Australian patent for PrimeC continues this IP‑expansion trend supporting long‑term development.

Regulatory & Risk Context

Active S-3 Shelf · $150,000,000

Shelf Active

Active S-3 Shelf Registration 2026-01-29

$150,000,000 registered capacity

An effective Form F-3 shelf filed on Jan 29, 2026 would allow NeuroSense to offer up to $150,000,000 of various securities and supports an at-the-market program of up to $6,525,000 in ordinary shares. The filing also carries forward $85,778,066 of unsold securities from a prior F-3 and notes substantial doubt about the company’s ability to continue as a going concern, underscoring reliance on future financings under this shelf and ATM.

Market Pulse Summary

This announcement adds an Australian patent for PrimeC, extending coverage through 2042 and reinforc...

Analysis

This announcement adds an Australian patent for PrimeC, extending coverage through 2042 and reinforcing NeuroSense’s global IP strategy alongside existing U.S. protection. It complements prior milestones such as FDA clearance for a pivotal Phase 3 ALS study and positive Phase 2 safety data in Alzheimer’s disease. Investors may track how this broadened exclusivity supports future partnering or commercialization discussions, while also weighing the company’s recently filed $150,000,000 shelf registration and overall funding requirements.

Key Terms

amyotrophic lateral sclerosis, neuroinflammation, extended-release formulation, phase 3, +1 more

5 terms

amyotrophic lateral sclerosis medical

"potential commercialization of PrimeC in ALS, Alzheimer's disease and other neurodegenerative"

A progressive disease in which nerve cells that control voluntary muscles gradually fail, leading to loss of movement, speech and eventually breathing — like an electrical wiring system in the body slowly shorting out. It matters to investors because there are few effective treatments, so clinical trial results, regulatory approvals, new therapies or diagnostics can rapidly change patient care, market opportunity and company valuations.

neuroinflammation medical

"including neuroinflammation, iron dysregulation, and miRNA dysregulation"

Neuroinflammation is the brain or spinal cord’s immune reaction to injury, infection, or abnormalities, where cells and molecules become active to protect or repair nervous tissue. It matters to investors because it underlies many neurological diseases and is a common target for drugs and diagnostic tools; positive or negative trial results, safety signals, or new therapies can change a company’s value much like a major repair plan or recall would affect a carmaker’s prospects.

extended-release formulation technical

"a synchronized, extended-release formulation specifically engineered to deliver both agents"

An extended-release formulation is a medicine designed to release its active ingredient slowly over an extended period instead of all at once, like a timed sprinkler that waters a lawn gradually rather than flooding it. For investors, it matters because this design can improve patient convenience and adherence, support premium pricing, extend commercial life versus immediate-release versions, and create different regulatory and competitive dynamics that affect sales and profitability.

phase 3 medical

"PrimeC is Phase 3-ready in ALS, following positive Phase 2b PARADIGM results"

Phase 3 is the late-stage clinical testing step for a new drug or medical treatment, where the product is given to large groups of patients to confirm effectiveness, monitor side effects, and compare it to standard care. Successful Phase 3 results are often the final scientific hurdle before regulators decide on approval and market launch—like passing a final exam before graduation—and can sharply change a company's valuation and future revenue prospects.

phase 2b medical

"PrimeC is Phase 3-ready in ALS, following positive Phase 2b PARADIGM results"

Phase 2b is a stage in the development of a new medicine or treatment where researchers test its effectiveness and safety in a larger group of people. This step helps determine whether the treatment works well enough to move forward and if it has manageable side effects, which is important for investors because successful results can lead to potential approval and market opportunity.

AI-generated analysis. Not financial advice.

Strengthens Global IP Portfolio for PrimeC Through 2042

CAMBRIDGE, Mass., Feb. 9, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today announced that the Australian Patent Office (IP Australia) has granted Australian Patent No. 2022370513, entitled "Compositions Comprising Ciprofloxacin and Celecoxib," representing another strategic step in the continued expansion of the Company's global intellectual property protection for PrimeC.

The granted Australian patent, following prior approval of the corresponding U.S. patent (12,097,185), further expands NeuroSense's patent  protection across key global markets and reinforces the Company's exclusivity strategy for PrimeC, with patent coverage extending through October 2042. NeuroSense continues to strengthen the company's global intellectual property estate and to support the long-term development and potential commercialization of PrimeC in ALS, Alzheimer's disease and other neurodegenerative indications.

 "Securing patent protection in Australia, in addition to the already granted patent in the US, is an important step in executing our global IP protection strategy for PrimeC," said Alon Ben-Noon, Chief Executive Officer of NeuroSense. "As we advance PrimeC toward pivotal development and potential commercialization, building a broad, durable IP estate across major jurisdictions is central to supporting long-term value creation."

PrimeC is a proprietary fixed-dose oral therapy combining ciprofloxacin and celecoxib in a synchronized, extended-release formulation specifically engineered to deliver both agents in a coordinated manner - a key differentiator versus simple co-administration. The formulation enables consistent exposure across multiple disease pathways implicated in ALS, including neuroinflammation, iron dysregulation, and miRNA dysregulation, supporting a multi-target disease-modifying approach.

PrimeC is Phase 3-ready in ALS, following positive Phase 2b PARADIGM results and FDA clearance of the pivotal Phase 3 protocol.

About NeuroSense

NeuroSense Therapeutics, Ltd. is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. NeuroSense believes that these diseases, which include amyotrophic lateral sclerosis (ALS), Alzheimer's disease and Parkinson's disease, among others, represent one of the most significant unmet medical needs of our time, with limited effective therapeutic options available for patients to date. Due to the complexity of neurodegenerative diseases and based on strong scientific research on a large panel of related biomarkers, NeuroSense's strategy is to develop combined therapies targeting multiple pathways associated with these diseases.

For additional information, we invite you to visit our website and follow us on LinkedIn, YouTube and X. Information that may be important to investors may be routinely posted on our website and these social media channels.

About PrimeC

PrimeC, NeuroSense's lead drug candidate, is a novel extended-release oral formulation composed of a unique fixed-dose combination of two FDA-approved drugs: ciprofloxacin and celecoxib. PrimeC is designed to synergistically target several key mechanisms of ALS and AD, that contribute to neuron degeneration, inflammation, iron accumulation and impaired ribonucleic acid ("RNA") regulation to potentially inhibit the progression of ALS and AD.

About ALS

Amyotrophic lateral sclerosis ("ALS") is an incurable neurodegenerative disease that causes complete paralysis and death within 2-5 years from diagnosis. Every year, more than 5,000 people are diagnosed with ALS in the U.S. alone, with an annual disease burden of $1 billion. The number of people living with ALS is expected to grow by 24% by 2040 in the U.S. and EU.

About Alzheimer's Disease
Alzheimer's disease (AD) is a progressive neurodegenerative disorder and the leading cause of dementia worldwide, affecting more than 30 million people globally. AD is characterized by memory loss, cognitive decline, and behavioral changes, and currently has no cure. Existing therapies provide only limited symptomatic relief, leaving a significant unmet need for disease-modifying treatments that can slow or halt progression. Given the complexity of AD, approaches that target multiple disease mechanisms simultaneously, such as PrimeC, hold potential to deliver meaningful therapeutic advances for patients and their families.

Forward-Looking Statements

This press release contains "forward-looking statements" that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "aim," "should," "will" "would," or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on NeuroSense Therapeutics' current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict and include statements regarding the timing of regulatory filings, meetings and regulatory decisions. Further, certain forward-looking statements, including statements regarding the length of patent coverage, are based on assumptions as to future events that may not prove to be accurate. The future events and trends may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward looking statements. These risks include the uncertainty regarding outcomes and the timing of current and future clinical trials; timing for reporting data, including from the study of PrimeC in Alzheimer's disease; that the study will not be successful; the ability of NeuroSense to remain listed on Nasdaq; and other risks and uncertainties set forth in NeuroSense's filings with the Securities and Exchange Commission (SEC). You should not rely on these statements as representing our views in the future. More information about the risks and uncertainties affecting NeuroSense is contained under the heading "Risk Factors" in the Annual Report on Form 20-F filed with the Securities and Exchange Commission on April 7, 2025 and NeuroSense's subsequent filings with the SEC. Forward-looking statements contained in this announcement are made as of this date, and NeuroSense undertakes no duty to update such information except as required under applicable law.

Logo - https://mma.prnewswire.com/media/1707291/NeuroSense_Therapeutics_Logo.jpg

 

 

View original content:https://www.prnewswire.com/news-releases/neurosense-expands-global-ip-protection-strategy-with-granted-australian-patent-covering-primec-composition-302682567.html

SOURCE NeuroSense

FAQ

What patent did NeuroSense (NRSN) receive in Australia on February 9, 2026?

NeuroSense received Australian Patent No. 2022370513 covering compositions of ciprofloxacin and celecoxib. According to the company, this grant protects the PrimeC composition and complements an already granted U.S. patent (12,097,185).

How long does the Australian patent for PrimeC (NRSN) provide protection?

The Australian patent extends PrimeC patent coverage through October 2042. According to the company, this timeline supports the firm’s global exclusivity strategy as PrimeC progresses toward pivotal development.

Does the Australian patent for PrimeC affect NeuroSense's U.S. patent position (NRSN)?

Yes. The Australian grant follows a corresponding U.S. patent (12,097,185), reinforcing international IP protection. According to the company, the two grants expand exclusivity across key global markets for PrimeC.

What does the PrimeC patent mean for NeuroSense's commercialization plans (NRSN)?

The patent strengthens intellectual property that may support future commercialization efforts. According to the company, building a broad IP estate is central to supporting long-term value creation as PrimeC advances.

What is PrimeC's clinical status after the Australian patent grant for NeuroSense (NRSN)?

PrimeC is described as Phase 3-ready in ALS following positive Phase 2b PARADIGM results. According to the company, the FDA has cleared the pivotal Phase 3 protocol, aligning IP protection with development plans.